Last reviewed · How we verify

IN-C006 Peri inj. — Competitive Intelligence Brief

IN-C006 Peri inj. (IN-C006 Peri inj.) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immune checkpoint inhibitor. Area: Oncology.

phase 3 Immune checkpoint inhibitor PD-1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

IN-C006 Peri inj. (IN-C006 Peri inj.) — HK inno.N Corporation. IN-C006 Peri inj. is a drug that targets the PD-1/PD-L1 pathway.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
IN-C006 Peri inj. TARGET IN-C006 Peri inj. HK inno.N Corporation phase 3 Immune checkpoint inhibitor PD-1
Tevimbra TISLELIZUMAB Beigene marketed Programmed Death Receptor-1 Blocking Antibody [EPC] Pd-1 2025-01-01
Penpulimab kcqx PENPULIMAB Akeso Biopharma marketed Pd-1 2025-01-01
Loqtorzi TORIPALIMAB Coherus Biosciences Inc marketed Programmed Death Receptor-1 Blocking Antibody [EPC] Pd-1 2024-01-01
Unloxcyt COSIBELIMAB Checkpoint Therapeutics Inc marketed Programmed Death Ligand-1 Blocker [EPC] Pd-1 2024-01-01
Jemperli DOSTARLIMAB GSK marketed Programmed Death Receptor-1 Blocking Antibody [EPC] PD-1 2021-01-01
Libtayo CEMIPLIMAB Regeneron Pharmaceuticals marketed PD-1 2018-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immune checkpoint inhibitor class)

  1. Sun Pharma Advanced Research Company Limited · 2 drugs in this class
  2. Brenda Cooper, MD · 1 drug in this class
  3. Grace Therapeutics Inc. · 1 drug in this class
  4. EMS · 1 drug in this class
  5. GERCOR - Multidisciplinary Oncology Cooperative Group · 1 drug in this class
  6. Glycotope GmbH · 1 drug in this class
  7. Bristol-Myers Squibb · 1 drug in this class
  8. HK inno.N Corporation · 1 drug in this class
  9. Hanlim Pharm. Co., Ltd. · 1 drug in this class
  10. Assistance Publique - Hôpitaux de Paris · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IN-C006 Peri inj. — Competitive Intelligence Brief. https://druglandscape.com/ci/in-c006-peri-inj. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: